Developer docs
API playgroundTry for free, no card

Search company profiles

Comend

Full company profile

uuid000385u

Namestring
Comend
Legal namestring
Comend Inc.
Websiteurl
comend.io
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Comend Inc. is a Canadian SaaS company founded in 2023 and headquartered in Mississauga, Ontario, that operates a two-sided marketplace connecting rare disease patient advocacy groups (PAGs) with academic researchers, contract research organizations, consultants, and biopharmaceutical companies. Its core product is a web-based research platform built on Google Cloud infrastructure (with a signed Business Associate Agreement to support HIPAA compliance) that lets patient groups organize therapeutic research projects via Research Plan templates, manage pre-clinical toolkits containing biosamples, disease models, and clinical datasets, and broadcast Requests for Proposals (RFPs) to a curated list of academics and service providers. A separate Researcher Hub at researcher.comend.io provides academics, CROs, biotech, pharma, and consultants with profile creation and marketplace discovery, while a multi-tenant architecture enforces app isolation and per-organization access controls.

The platform's product surface is organized into five modules — Research Plans, Pre-clinical Toolkit, Requests for Proposals, Marketplace, and a dedicated Researcher Hub — and is augmented by Librarey, the founders' earlier rare-disease project, and a CRO marketplace layer added through a 2025 partnership with Odylia Therapeutics. Comend maintains OAuth 2.0 authentication, role-based access, encrypted data at rest and in transit, rate limiting, bot detection, and audit logging, with HIPAA-aligned readiness even though no protected health information is currently held.

Comend's commercial model is a freemium-plus-services construct: the core platform is provided free of charge to patient advocacy groups (the supply side, currently comprising 20+ foundations including The Rory Belle Foundation, AGSAA, CurePDE Foundation, PBD Project, Project 8p, and Odylia Therapeutics), while revenue is intended to be generated by helping biopharmaceutical companies identify and engage with rare disease research opportunities surfaced from the curated PAG ecosystem. Go-to-market relies on direct web self-service onboarding, organic social (LinkedIn, Instagram, X), and accelerator-driven enterprise introductions via PharmStars, under which Comend has met with multiple big pharma companies and received investment from the PharmStars fund. The company is privately held, has raised $765,000 from Character, Drive Capital, and PharmStars, and operates with a 1-10 person team plus an advisory bench spanning drug development and rare disease advocacy.

Short descriptiontext

Comend operates a two-sided SaaS marketplace that connects rare disease patient advocacy groups with researchers, CROs, and biopharma, offering free research coordination tools to PAGs and monetizing biopharma access to curated rare disease opportunities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease platform, patient advocacy tools, research marketplace, biopharma partnership services, preclinical asset management
Industry2 codes
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Research Collaboration Platform
Revenue model2 records
1Biopharma Partnership Services
TypeProfessional Services
Description

Comend generates revenue by helping biopharma companies identify opportunities in rare diseases. Patient groups use the free platform to organize and showcase their research, which Comend then surfaces to pharmaceutical companies seeking rare disease research opportunities.

comend.io
2Platform Services for Patient Groups
TypeFreemium
Description

The core platform is free for patient groups, serving as the supply side of the marketplace. Revenue is derived from the demand side (biopharma) accessing the curated patient group ecosystem.

comend.io
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Free for patient groups
ModelFreemiumBilling cadenceOthers
Notes

Patient groups receive free access to all platform features including research plans, pre-clinical toolkit management, RFP broadcasting, and marketplace presence.

comend.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Comend operates a two-sided SaaS marketplace that lets rare disease patient advocacy groups organize research plans, manage pre-clinical toolkits (biosamples, disease models, clinical datasets), and broadcast Requests for Proposals (RFPs) to researchers, CROs, and service providers. The platform also lets researchers, CROs, biotech, and pharma discover patient groups, research plans, biosamples, disease models, clinical datasets, and RFPs through a unified marketplace. Patient groups access all features for free, while Comend generates revenue by helping biopharma companies identify and evaluate rare disease research opportunities surfaced through the curated ecosystem.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Comend operates as a unified research platform for genetic conditions, connecting patient groups with researchers to accelerate rare disease drug development. The core Comend Platform serves as the central hub, supplemented by specialized modules including Research Plans (for mapping therapeutic goals and projects), Pre-clinical Toolkit (for managing biosamples, disease models, and clinical datasets), Requests for Proposals (for broadcasting research opportunities), and the Marketplace (for discovering and connecting patient groups, tools, and partners). The platform also includes a dedicated Researcher Hub at researcher.comend.io for academic users. Additionally, Comend's creators developed Librarey as their first project in this space.

Product and service3 records
1Comend Platform
CategoryResearch Collaboration Platform
Description

The research platform for genetic conditions that connects patient groups with researchers, enabling discovery of projects, tools, and partners in one unified marketplace. Includes research plans, pre-clinical toolkit management, and RFP broadcasting capabilities.

2Comend Marketplace
CategoryMarketplace / Discovery
Description

Central hub for browsing patient groups, biosamples, disease models, clinical datasets, research plans, and Requests for Proposals on the Comend platform. Serves researchers, CROs, biotech, pharma, and consultants seeking rare disease opportunities.

3Researcher Hub
CategoryResearcher Portal
Description

Researcher-facing portal at researcher.comend.io for completing profiles and accessing Comend's marketplace of research plans, biosamples, disease models, clinical datasets, and RFPs. Built for academics, CROs, biotech, pharma, and consultants.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-21
Description

Comend partnered with Odylia to bring patient advocacy groups (PAGs) a marketplace of CROs and expanded research capabilities. Odylia is a nonprofit dedicated to accelerating treatments for rare diseases through gene therapy programs.

2Librarey
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Librarey is credited as the creator of Comend. The platform is described as 'From the creators of Librarey', indicating Librarey is the parent project or founding team that developed Comend as their second venture in the rare disease research space.

comend.io
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TrialX operates a patient recruitment and clinical trial matching platform connecting patients and researchers. It is the closest direct peer in matching rare disease and other patient populations to study opportunities, sharing Comend's core marketplace model.

2Antidote (formerly TrialReach)
TypeDirect peer
Description

Antidote runs a patient recruitment marketplace for clinical trials, including rare disease populations. It competes head-to-head with Comend on the demand side — connecting biopharma and trial sponsors with engaged patient communities.

TypeBroad incumbent
Description

Medable is a well-capitalized decentralized clinical trial technology platform serving pharma and CROs. While broader in scope than Comend, it increasingly pursues patient engagement workflows that overlap with Comend's research coordination vision.

TypeBroad incumbent
Description

Veeva is a large incumbent life sciences cloud platform spanning clinical, regulatory, and commercial workflows. Its clinical operations suite addresses adjacent biopharma R&D needs and could plausibly extend into patient group coordination.

TypeBroad incumbent
Description

IQVIA is the largest life sciences services and technology provider globally, with deep clinical trial and real-world data offerings. It is a broad incumbent that competes for the same biopharma R&D budgets Comend is targeting.

TypeBroad incumbent
Description

Within3 provides a life sciences engagement platform for medical affairs, including investigator and patient community engagement. It serves the same biopharma buyers as Comend with a more established, broader product suite.

7Mendel (Mendel AI)
TypeEmerging player
Description

Mendel uses AI to match patients to clinical trials and structure clinical data. As an emerging player, it overlaps with Comend's goal of accelerating rare disease trial enrollment and translational research.

TypeEmerging player
Description

Power is an emerging patient engagement and clinical trial platform with a focus on community and decentralized participation. It targets overlapping biopharma customers and shares Comend's patient-centric design philosophy.

TypeBroad incumbent
Description

BBK Worldwide is a long-established patient recruitment and engagement agency for clinical trials, including rare disease programs. It represents the services-oriented incumbent model competing for the same biopharma marketing budgets.

TypeBroad incumbent
Description

Citeline provides drug development intelligence and trial pipeline data to biopharma. While it sells intelligence rather than a marketplace, it is a comparable source of rare disease deal-flow for the same pharma customers Comend targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Comend

Research Collaboration Platformcomend.io

Comend operates a two-sided SaaS marketplace that connects rare disease patient advocacy groups with researchers, CROs, and biopharma, offering free research coordination tools to PAGs and monetizing biopharma access to curated rare disease opportunities.

What Comend does

Comend Inc. is a Canadian SaaS company founded in 2023 and headquartered in Mississauga, Ontario, that operates a two-sided marketplace connecting rare disease patient advocacy groups (PAGs) with academic researchers, contract research organizations, consultants, and biopharmaceutical companies. Its core product is a web-based research platform built on Google Cloud infrastructure (with a signed Business Associate Agreement to support HIPAA compliance) that lets patient groups organize therapeutic research projects via Research Plan templates, manage pre-clinical toolkits containing biosamples, disease models, and clinical datasets, and broadcast Requests for Proposals (RFPs) to a curated list of academics and service providers. A separate Researcher Hub at researcher.comend.io provides academics, CROs, biotech, pharma, and consultants with profile creation and marketplace discovery, while a multi-tenant architecture enforces app isolation and per-organization access controls.

The platform's product surface is organized into five modules — Research Plans, Pre-clinical Toolkit, Requests for Proposals, Marketplace, and a dedicated Researcher Hub — and is augmented by Librarey, the founders' earlier rare-disease project, and a CRO marketplace layer added through a 2025 partnership with Odylia Therapeutics. Comend maintains OAuth 2.0 authentication, role-based access, encrypted data at rest and in transit, rate limiting, bot detection, and audit logging, with HIPAA-aligned readiness even though no protected health information is currently held.

Comend's commercial model is a freemium-plus-services construct: the core platform is provided free of charge to patient advocacy groups (the supply side, currently comprising 20+ foundations including The Rory Belle Foundation, AGSAA, CurePDE Foundation, PBD Project, Project 8p, and Odylia Therapeutics), while revenue is intended to be generated by helping biopharmaceutical companies identify and engage with rare disease research opportunities surfaced from the curated PAG ecosystem. Go-to-market relies on direct web self-service onboarding, organic social (LinkedIn, Instagram, X), and accelerator-driven enterprise introductions via PharmStars, under which Comend has met with multiple big pharma companies and received investment from the PharmStars fund. The company is privately held, has raised $765,000 from Character, Drive Capital, and PharmStars, and operates with a 1-10 person team plus an advisory bench spanning drug development and rare disease advocacy.

Comend firmographics

Firmographics
Name
Comend
Legal name
Comend Inc.
Website
https://comend.io
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Comend operates a two-sided SaaS marketplace that connects rare disease patient advocacy groups with researchers, CROs, and biopharma, offering free research coordination tools to PAGs and monetizing biopharma access to curated rare disease opportunities.
Ownership category
akta.pro rank

Comend industry classification

Industry
Product category
Research Collaboration Platform
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Rare disease platform
  • Patient advocacy tools
  • Research marketplace
  • Biopharma partnership services
  • Preclinical asset management

Where Comend is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Comend business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biopharma Partnership Services: Comend generates revenue by helping biopharma companies identify opportunities in rare diseases. Patient groups use the free platform to organize and showcase their research, which Comend then surfaces to pharmaceutical companies seeking rare disease research opportunities.
  2. Platform Services for Patient Groups: The core platform is free for patient groups, serving as the supply side of the marketplace. Revenue is derived from the demand side (biopharma) accessing the curated patient group ecosystem.

Pricing tiers

ModelBillingPrice
FreemiumOthersFree for patient groups

Distribution channels1 record

Marketing channels5 records

Comend product offering

Product offering

Core offering

Comend operates a two-sided SaaS marketplace that lets rare disease patient advocacy groups organize research plans, manage pre-clinical toolkits (biosamples, disease models, clinical datasets), and broadcast Requests for Proposals (RFPs) to researchers, CROs, and service providers. The platform also lets researchers, CROs, biotech, and pharma discover patient groups, research plans, biosamples, disease models, clinical datasets, and RFPs through a unified marketplace. Patient groups access all features for free, while Comend generates revenue by helping biopharma companies identify and evaluate rare disease research opportunities surfaced through the curated ecosystem.

Product overview

Comend operates as a unified research platform for genetic conditions, connecting patient groups with researchers to accelerate rare disease drug development. The core Comend Platform serves as the central hub, supplemented by specialized modules including Research Plans (for mapping therapeutic goals and projects), Pre-clinical Toolkit (for managing biosamples, disease models, and clinical datasets), Requests for Proposals (for broadcasting research opportunities), and the Marketplace (for discovering and connecting patient groups, tools, and partners). The platform also includes a dedicated Researcher Hub at researcher.comend.io for academic users. Additionally, Comend's creators developed Librarey as their first project in this space.

Differentiator

Problem solved

Functional benefit

Products and services

  • Comend Platform The research platform for genetic conditions that connects patient groups with researchers, enabling discovery of projects, tools, and partners in one unified marketplace. Includes research plans, pre-clinical toolkit management, and RFP broadcasting capabilities.
  • Comend Marketplace Central hub for browsing patient groups, biosamples, disease models, clinical datasets, research plans, and Requests for Proposals on the Comend platform. Serves researchers, CROs, biotech, pharma, and consultants seeking rare disease opportunities.
  • Researcher Hub Researcher-facing portal at researcher.comend.io for completing profiles and accessing Comend's marketplace of research plans, biosamples, disease models, clinical datasets, and RFPs. Built for academics, CROs, biotech, pharma, and consultants.

Companies that use Comend

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Comend technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Comend partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and foundational.

  • Odylia TherapeuticscoreStrategic or Co-development Partner · 21 May 2025Comend partnered with Odylia to bring patient advocacy groups (PAGs) a marketplace of CROs and expanded research capabilities. Odylia is a nonprofit dedicated to accelerating treatments for rare diseases through gene therapy programs.
  • LibrareyfoundationalStrategic or Co-development PartnerLibrarey is credited as the creator of Comend. The platform is described as 'From the creators of Librarey', indicating Librarey is the parent project or founding team that developed Comend as their second venture in the rare disease research space.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Comend competitors and assessment

Company assessment

Direct peers

  • TrialX: TrialX operates a patient recruitment and clinical trial matching platform connecting patients and researchers. It is the closest direct peer in matching rare disease and other patient populations to study opportunities, sharing Comend's core marketplace model.
  • Antidote (formerly TrialReach): Antidote runs a patient recruitment marketplace for clinical trials, including rare disease populations. It competes head-to-head with Comend on the demand side — connecting biopharma and trial sponsors with engaged patient communities.

Broad incumbents

  • Medable: Medable is a well-capitalized decentralized clinical trial technology platform serving pharma and CROs. While broader in scope than Comend, it increasingly pursues patient engagement workflows that overlap with Comend's research coordination vision.
  • Veeva Systems: Veeva is a large incumbent life sciences cloud platform spanning clinical, regulatory, and commercial workflows. Its clinical operations suite addresses adjacent biopharma R&D needs and could plausibly extend into patient group coordination.
  • IQVIA: IQVIA is the largest life sciences services and technology provider globally, with deep clinical trial and real-world data offerings. It is a broad incumbent that competes for the same biopharma R&D budgets Comend is targeting.
  • Within3: Within3 provides a life sciences engagement platform for medical affairs, including investigator and patient community engagement. It serves the same biopharma buyers as Comend with a more established, broader product suite.
  • BBK Worldwide: BBK Worldwide is a long-established patient recruitment and engagement agency for clinical trials, including rare disease programs. It represents the services-oriented incumbent model competing for the same biopharma marketing budgets.
  • Citeline (Pharma Intelligence): Citeline provides drug development intelligence and trial pipeline data to biopharma. While it sells intelligence rather than a marketplace, it is a comparable source of rare disease deal-flow for the same pharma customers Comend targets.

Emerging players

  • Mendel (Mendel AI): Mendel uses AI to match patients to clinical trials and structure clinical data. As an emerging player, it overlaps with Comend's goal of accelerating rare disease trial enrollment and translational research.
  • Power (Power Life Science): Power is an emerging patient engagement and clinical trial platform with a focus on community and decentralized participation. It targets overlapping biopharma customers and shares Comend's patient-centric design philosophy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Comend social profiles

Digital presence

Comend compliance and trust

Trust signal

Compliance1 record

Comend financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Comend leadership team

Management profile

Number of profiles

Profiles12 records

Comend funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Comend M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comend

What does Comend do?

Comend operates a two-sided SaaS marketplace that lets rare disease patient advocacy groups organize research plans, manage pre-clinical toolkits (biosamples, disease models, clinical datasets), and broadcast Requests for Proposals (RFPs) to researchers, CROs, and service providers. The platform also lets researchers, CROs, biotech, and pharma discover patient groups, research plans, biosamples, disease models, clinical datasets, and RFPs through a unified marketplace. Patient groups access all features for free, while Comend generates revenue by helping biopharma companies identify and evaluate rare disease research opportunities surfaced through the curated ecosystem.

Is Comend a public or private company?

Comend is a private company. It is classified as venture growth investor backed and is currently operating.

When was Comend founded?

Comend was founded in 2023. It employs 1 to 10 people.

Where is Comend based?

Comend is headquartered in Toronto, Canada, in the North America region.

How does Comend make money?

Two revenue lines are on record. Biopharma Partnership Services are the primary driver. The others are platform Services for Patient Groups.

Who are Comend's main competitors?

Direct peers on record are TrialX and Antidote (formerly TrialReach). Broad incumbents are Medable, Veeva Systems, IQVIA, Within3, BBK Worldwide and Citeline (Pharma Intelligence). Emerging players are Mendel (Mendel AI) and Power (Power Life Science).

Does Comend have an API?

Yes. All backend services are guarded by authentication and strict access policies. Protected API endpoints with rate limiting and bot detection. The platform supports social login authentication (Google, Facebook, LinkedIn via OAuth 2.0) and provides user-friendly cookie management controls through CookieYes.

What industry is Comend in?

Comend's product category is Research Collaboration Platform. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales